PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian f... скачать в хорошем качестве

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian f...

Dr Matteo Lambertini speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about updates from PROMISE-GIM6. He explains that the phase III trial assessed GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with hormone receptor-positive early breast cancer. He notes that this is not just to preserve fertility, but to avoid other side effects that may impact the patient's quality of life following treatment. Dr Lambertini reports that the final analysis of the trial at a median follow-up of 12.4 years provides reassuring evidence on the safety of this approach as a strategy to preserve ovarian function in these patients. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php